The original version of this article unfortunately contained affiliation and textual errors. This has been corrected with this erratum.
Affiliation of eleventh author was incorrectly assigned. Dr. William Guyer is affiliated with Gilead Sciences Inc, Foster City, CA, USA.
In Results section, Safety Profile subsection, the sentence, 'Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were treated with TDF' should read as below:
Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were retreated with TDF.
In Table 2 , header 'Mean HBV DNA change from baseline, log 10 IU/mL (SD)' row 3 is missing 'B' in genotype. Revised version of the Table 2 is given below.
The original article can be found online at https ://doi.org/10.1007/ s1062 0-018-5251-9. 
